| Literature DB >> 33737137 |
Muhammad Imran Nisar1, Nadia Ansari2, Farah Khalid2, Mashal Amin2, Hamna Shahbaz2, Aneeta Hotwani2, Najeeb Rehman2, Sierra Pugh3, Usma Mehmood2, Arjumand Rizvi2, Arslan Memon4, Zahoor Ahmed4, Ashfaque Ahmed4, Junaid Iqbal2, Ali Faisal Saleem2, Uzma Bashir Aamir5, Daniel B Larremore6, Bailey Fosdick3, Fyezah Jehan7.
Abstract
OBJECTIVE: To determine population-based estimates of coronavirus disease 2019 (COVID-19) in a densely populated urban community of Karachi, Pakistan.Entities:
Keywords: Antibody; COVID-19; Pakistan; Seroepidemiology; Seroprevalence; Surveillance
Mesh:
Substances:
Year: 2021 PMID: 33737137 PMCID: PMC8752032 DOI: 10.1016/j.ijid.2021.03.040
Source DB: PubMed Journal: Int J Infect Dis ISSN: 1201-9712 Impact factor: 3.623
Figure 1Study area and total population.
Figure 2Flow chart of participants in (A) Phase 1, (B) Phase 2 and (C) Phase 3.
General characteristics of the study participants.
| District East | Districts | District Malir | ||||
|---|---|---|---|---|---|---|
| Characteristics | Phase 1 ( | Phase 2 ( | Phase 3 ( | Phase 1 ( | Phase 2 ( | Phase 3 ( |
| Gender, male, | 256 (51.2%) | 225 (45.0%) | 211 (42.2%) | 207 (41.4%) | 199 (39.5%) | 206 (41.1%) |
| Age in years, mean (SD) | 26.2 (17.9%) | 25.9 (16.7%) | 27.1 (17.7%) | 28.5 (17.9%) | 24.32 (16.7%) | 26 (16.7%) |
| Age group, years, | ||||||
| 0–4 | 35 (7.0%) | 22 (4.4%) | 31 (6.2%) | 26 (5.2%) | 33 (6.6%) | 29 (5.8%) |
| 5–9 | 57 (11.4%) | 54 (10.8%) | 56 (11.2%) | 52 (10.4%) | 74 (14.7%) | 75 (15.0%) |
| 10–18 | 107 (21.4%) | 139 (27.8%) | 91 (18.2%) | 86 (17.2%) | 120 (23.9%) | 87 (17.4%) |
| 19–39 | 185 (37.0%) | 170 (34.0%) | 206 (41.2%) | 203 (40.6%) | 186 (37.0%) | 195 (38.9%) |
| 40–59 | 83 (16.6%) | 97 (19.4%) | 84 (16.8%) | 103 (20.6%) | 65 (12.9%) | 90 (18.0%) |
| ≥60 | 33 (6.6%) | 18 (3.6%) | 32 (6.4%) | 30 (6.0%) | 25 (5.0%) | 25 (5.0%) |
| Household size, mean (SD) | 6.1 (4.17) | 6.6 (3.6) | 5.7 (2.3) | 6 (2.8) | 5.89 (3.2) | 5.6 (2.6) |
| Working outside home, | 155 (31.0%) | 145 (29.0%) | 107 (21.4%) | 143 (28.6%) | 124 (24.6%) | 116 (23.2) |
| Comorbidities, | ||||||
| None | 453 (92.3%) | 463 (93.0%) | 471 (94.2%) | 473 (94.6%) | 479 (95.0%) | 482 (96.2%) |
| Diabetes | 20 (4.0%) | 14 (2.8%) | 8 (1.6%) | 6 (1.2%) | 10 (2.0%) | 5 (1.0%) |
| Hypertension | 14 (2.8%) | 13 (2.6%) | 16 (3.2%) | 16 (3.2%) | 11 (2.2%) | 14 (2.8%) |
| Asthma or allergy | 3 (0.6%) | 3 (0.6%) | 3 (0.6%) | 1 (0.2%) | 0 (0.0%) | 0 (0.0%) |
| Chronic hepatitis | 2 (0.4%) | 3 (0.6%) | 1 (0.2%) | 3 (0.6%) | 3 (0.6%) | 0 (0.0%) |
| Chronic heart disease | 0 (0.0%) | 3 (0.6%) | 1 (0.2%) | 1 (0.2%) | 1 (0.2%) | 1 (0.2%) |
| Asymptomatic | 435 (87.0%) | 453 (90.6%) | 471 (94.2%) | 472 (94.4%) | 487 (96.6%) | 473 (94.4%) |
| Sought care | 9 (1.8%) | 9 (1.8%) | 2 (0.4%) | 3 (0.6%) | 4 (0.8%) | 0 (0.0%) |
| Hospitalization | 1 (0.2%) | 5 (1.0%) | 0 (0%) | 1 (0.2%) | 0 (0.0%) | 0 (0.0%) |
| History of travel | 2 (0.4%) | 11 (2.2%) | 7 (1.4%) | 8 (1.6%) | 1 (0.2%) | 4 (0.8%) |
| Contact with suspected or confirmed cases of COVID-19 | 1 (0.2%) | 1 (0.2%) | 2 (0.4%) | 0 (0.0%) | 1 (0.2%) | 1 (0.2%) |
COVID-19, coronavirus disease 2019; SD, standard deviation.
Figure 3Comparison of trends in coronavirus-disease-2019-positive cases from District East and study sampling sites, and estimated seroprevalence in Phases 1, 2 and 3.
Age- and gender-based prevalence of coronavirus disease 2019 in District East and District Malir for Phases 2 and 3.a
| Variables | Phase 2 | Phase 3 | |||
|---|---|---|---|---|---|
| Gender | Age (years) | District East | District Malir | District East | District Malir |
| Female | 0–4 | 0.14 (0.04–0.25) | 0.08 (0.02–0.14) | 0.20 (0.09–0.30) | 0.13 (0.07–0.21) |
| Female | 5–9 | 0.13 (0.04–0.22) | 0.09 (0.04–0.15) | 0.20 (0.10–0.23) | 0.13 (0.07–0.19) |
| Female | 10–18 | 0.13 (0.05–0.21) | 0.09 (0.04–0.14) | 0.20 (0.12–0.23) | 0.12 (0.07–0.19) |
| Female | 19–39 | 0.15 (0.07–0.23) | 0.10 (0.05–0.16) | 0.24 (0.16–0.33) | 0.13 (0.08–0.19) |
| Female | 40–59 | 0.15 (0.07–0.26) | 0.08 (0.03–0.14) | 0.23 (0.15–0.33) | 0.14 (0.08–0.21) |
| Female | ≥60 | 0.15 (0.05–0.27) | 0.01 (0.04–0.19) | 0.21 (0.12–0.31) | 0.13 (0.06–0.19) |
| Male | 0–4 | 0.14 (0.04–0.25) | 0.08 (0.02–0.14) | 0.19 (0.09–0.29) | 0.12 (0.06–0.19) |
| Male | 5–9 | 0.13 (0.03–0.23) | 0.08 (0.03–0.14) | 0.19 (0.08–0.28) | 0.12 (0.06–0.19) |
| Male | 10–18 | 0.17 (0.09–0.28) | 0.01 (0.04–0.17) | 0.22 (0.14–0.32) | 0.14 (0.08–0.22) |
| Male | 19–39 | 0.15 (0.08–0.24) | 0.08 (0.03–0.13) | 0.22 (0.14–0.31) | 0.12 (0.07–0.18) |
| Male | 40–59 | 0.22 (0.10–0.40) | 0.08 (0.03–0.14) | 0.22 (0.14–0.35) | 0.13 (0.08–0.22) |
| Male | ≥60 | 0.14 (0.05–0.26) | 0.09 (0.03–0.15) | 0.21 (0.11–0.32) | 0.13 (0.07–0.20) |
Numbers are probability estimates with 95% CI.